Overview
Endothelin-converting enzyme (ECE) is a membrane-bound metalloprotease that catalyzes the final step in endothelin biosynthesis, cleaving inactive big endothelin into the active peptide endothelin-1. Discovered in the 1990s, ECE exists as two major isoforms (ECE-1 and ECE-2) with distinct tissue distributions. It plays a pivotal role in the regulation of vascular tone and is a target for cardiovascular therapeutics. ECE is primarily expressed in endothelial cells, neurons, and smooth muscle tissues. The enzyme's activity is critical for maintaining blood pressure homeostasis. Dysregulation of ECE has been implicated in hypertension, heart failure, and pulmonary arterial hypertension. Pharmaceutical inhibitors of ECE, such as phosphoramidon, are used experimentally to study endothelin pathways and develop antihypertensive drugs.
Physical and Chemical Properties
ECE is a zinc-dependent protease with a molecular weight ranging from 75 to 120 kDa, depending on glycosylation and isoform (ECE-1a/b/c/d or ECE-2). It functions optimally at neutral pH (6.5-7.5) and is inhibited by metal chelators like EDTA. The enzyme is sensitive to temperature, with activity declining above 37°C due to denaturation. Structural studies reveal ECE's homology to neprilysin, featuring a large extracellular catalytic domain and a short cytoplasmic tail. Its active site contains a conserved HExxH zinc-binding motif. ECE-1 localizes to the plasma membrane, while ECE-2 is predominantly intracellular, reflecting their distinct physiological roles in endothelin processing.
Main Applications
In research, ECE is used to study endothelin-mediated vasoconstriction and its role in cardiovascular diseases. It serves as a biomarker for endothelial dysfunction in hypertension models. Drug discovery programs target ECE to develop dual ECE/neprilysin inhibitors (e.g., SLV-306) for treating heart failure. Industrially, recombinant ECE is produced for high-throughput screening of inhibitors. Diagnostic applications include measuring ECE activity in patient sera to assess vascular health. In biotechnology, ECE cleavage sites are engineered into fusion proteins for controlled peptide release.
Safety and Storage
Lyophilized ECE should be stored at -20°C in a desiccator to prevent moisture absorption. Reconstituted enzyme aliquots are stable for 3-6 months at -80°C but lose ~10% activity per freeze-thaw cycle. Use protease-free buffers (e.g., 50 mM Tris-HCl, pH 7.4) for dilution. Safety protocols include wearing gloves and eye protection when handling. Although non-pathogenic, airborne powders may irritate respiratory membranes. Spills should be neutralized with 0.1 N NaOH before disposal. Activity assays should include controls (e.g., phosphoramidon) to confirm specificity.
B2B Procurement Guide
When sourcing ECE, prioritize suppliers providing Certificate of Analysis (CoA) with specific activity (e.g., ≥0.5 U/mg) and endotoxin levels (<1 EU/μg). For drug discovery, opt for human recombinant ECE-1 (UniProt P42892) over animal-derived versions to ensure translational relevance. Bulk orders (≥100 mg) typically offer 15-30% cost savings. Confirm shipping conditions (dry ice for proteins) and lead times (4-6 weeks for custom isoforms). Consider licensing requirements if using patented ECE variants (e.g., truncated forms for crystallography).
Related Manufacturers
- 主营：elisa试剂盒、生化试剂盒、抗体、细胞、pcr试剂盒
- 主营：内皮素转换酶1、试剂盒、ELISA试剂盒、ELISA检测试剂盒
- 主营：内皮素转换酶2、elisa试剂盒、试剂盒、抗体